Latent-Y: The Autonomous AI Agent for Drug Design at Scale

AI Briefing

• – AI-powered antibody design platform launches, automating weeks of work into hours, expands access to researchers
• – Latent-Y uses Latent-X2 model for drug-like antibody and peptide design, eliminating specialist infrastructure requirements
• – Latent Labs opens access to selected partners, enabling widespread adoption of autonomous drug discovery technology